Stock Track | GenFleet Therapeutics Plummets 11.85% Intraday After Clarification on Patent Disputes

Stock Track04-28 12:32

GenFleet Therapeutics-B (02595) experienced a significant intraday decline of 11.85% on Tuesday, as the stock plummeted during the trading session.

The sharp drop followed the company's clarification regarding its Pan RAS inhibitor drug candidate GFH276. GenFleet stated that GFH276 was developed using independent, proprietary intellectual property and is unrelated to patent or trade secret disputes referenced in correspondence from Revolution Medicines on RAS inhibitors.

In its announcement, the company emphasized it has no exposure to infringement or trade secret risks tied to those disputes and highlighted its global patent portfolio for the Pan RAS program, with core patent protection projected through 2044.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1145822667?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-28 12:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1145822667","market":"hk","top_or_hot":-1,"title":"Stock Track | GenFleet Therapeutics Plummets 11.85% Intraday After Clarification on Patent Disputes","media":"Stock Track","content":"<p>GenFleet Therapeutics-B (02595) experienced a significant intraday decline of 11.85% on Tuesday, as the stock plummeted during the trading session.</p><p>The sharp drop followed the company's clarification regarding its Pan RAS inhibitor drug candidate GFH276. GenFleet stated that GFH276 was developed using independent, proprietary intellectual property and is unrelated to patent or trade secret disputes referenced in correspondence from Revolution Medicines on RAS inhibitors.</p><p>In its announcement, the company emphasized it has no exposure to infringement or trade secret risks tied to those disputes and highlighted its global patent portfolio for the Pan RAS program, with core patent protection projected through 2044.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | GenFleet Therapeutics Plummets 11.85% Intraday After Clarification on Patent Disputes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | GenFleet Therapeutics Plummets 11.85% Intraday After Clarification on Patent Disputes\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-28 12:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GenFleet Therapeutics-B (02595) experienced a significant intraday decline of 11.85% on Tuesday, as the stock plummeted during the trading session.</p><p>The sharp drop followed the company's clarification regarding its Pan RAS inhibitor drug candidate GFH276. GenFleet stated that GFH276 was developed using independent, proprietary intellectual property and is unrelated to patent or trade secret disputes referenced in correspondence from Revolution Medicines on RAS inhibitors.</p><p>In its announcement, the company emphasized it has no exposure to infringement or trade secret risks tied to those disputes and highlighted its global patent portfolio for the Pan RAS program, with core patent protection projected through 2044.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02595","symbol_name":"劲方医药-B","start_time":0,"source_url":"","article_id":"1145822667","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1145822667","pubTimestamp":1777350767,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"GenFleet Therapeutics-B (02595) experienced a significant intraday decline of 11.85% on Tuesday, as the stock plummeted during the trading session.The sharp drop followed the company's clarification...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02595":"劲方医药-B"},"translate_title":"个股追踪|GenFleet Therapeutics澄清专利纠纷后盘中暴跌11.85%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02595":1},"content_text":"GenFleet Therapeutics-B (02595) experienced a significant intraday decline of 11.85% on Tuesday, as the stock plummeted during the trading session.The sharp drop followed the company's clarification regarding its Pan RAS inhibitor drug candidate GFH276. GenFleet stated that GFH276 was developed using independent, proprietary intellectual property and is unrelated to patent or trade secret disputes referenced in correspondence from Revolution Medicines on RAS inhibitors.In its announcement, the company emphasized it has no exposure to infringement or trade secret risks tied to those disputes and highlighted its global patent portfolio for the Pan RAS program, with core patent protection projected through 2044.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1145822667","isCrawlerRequest":true}